We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Clavis Pharma Receives Government Grant to Develop hENT1 Biomarker Assay for Targeted Therapy of AML Patients

News   Jun 01, 2011

 
Clavis Pharma Receives Government Grant to Develop hENT1 Biomarker Assay for Targeted Therapy of AML Patients
 
 
Advertisement
 

RELATED ARTICLES

New Test Can Target and Capture Most Lethal Cells in Fatal Brain Cancer

News

A laboratory test developed by a research team led by Johns Hopkins University bioengineers can accurately pinpoint, capture and analyze the deadliest cells in the most common and aggressive brain cancer in adults.

READ MORE

Light Beam Technique Detects Brain Injury "On the Spot"

News

A method for detecting traumatic brain injury at the point of care has been developed by scientists at the University of Birmingham.

READ MORE

Army Researchers Collaborate on Universal Antibody Test for COVID-19

News

Researchers with the U.S. Army Futures Command are part of a team that tested alternative ways to measure COVID-19 antibody levels, resulting in a process that is faster, easier and less expensive to use on a large scale.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Diagnostics Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE